Kyverna Therapeutics Announces Positive Results from KYSA-8 Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 21 2026
0mins
Should l Buy KYTX?
Kyverna Therapeutics announced positive primary analysis results from its registrational trial, KYSA-8, of miv-cel in stiff person syndrome. The data will be presented today in a late-breaking oral presentation at the American Academy of Neurology Annual Meeting in Chicago. In KYSA-8, a single dose of miv-cel delivered rapid, statistically significant and clinically meaningful improvements across all primary and secondary endpoints at 16 weeks, with the majority of patients regaining function, and all patients discontinuing chronic immunotherapies - outcomes not previously observed in SPS. Further, miv-cel was well-tolerated. "The results from our KYSA-8 registrational trial mark a defining moment for Kyverna, and more importantly, for patients living with stiff person syndrome," said Warner Biddle, Chief Executive Officer of Kyverna Therapeutics. "We see compelling evidence that a one-time therapy can reset the immune system, reverse the course of disease, and free patients from lifelong treatment burden. With no approved therapies, we believe miv-cel could redefine the treatment paradigm for this debilitating, progressive disease. We are preparing our BLA submission for this initial indication, and the data strengthen our confidence in miv-cel's therapeutic potential in myasthenia gravis, as well as other neurologic autoimmune diseases."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KYTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KYTX
Wall Street analysts forecast KYTX stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 10.230
Low
20.00
Averages
29.50
High
33.00
Current: 10.230
Low
20.00
Averages
29.50
High
33.00
About KYTX
Kyverna Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases. The Company’s lead chimeric antigen receptor (CAR) T-cell therapy candidate, KYV-101, is advancing through clinical development with Phase II trials for stiff person syndrome and myasthenia gravis, and two ongoing multi-center Phase I/II trials for patients with lupus nephritis. KYV-101 is an autologous, fully human CD19 CAR T-cell product candidate incorporating highly potent CD28 co-stimulation. The Company is also harnessing investigator-initiated trials and other KYSA studies, including in multiple sclerosis and systemic sclerosis, to inform the next priority indications for the Company to advance into late-stage development. Its pipeline includes next generation CAR T-cell therapies in both autologous and allogeneic formats with properties intended to be well suited for use in B cell-driven autoimmune diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kyverna Initiates Rolling BLA Process with FDA for miv-cel
- BLA Process Initiation: Kyverna Therapeutics (KYTX) has commenced the rolling Biologics License Application (BLA) process for its autoimmune CAR T therapy, miv-cel, marking a significant advancement in treating stiff person syndrome.
- Clinical Data Integration: The company has agreed with the FDA to include results from the KYSA-8 single-arm trial in the application, with the primary endpoint being the Timed 25-foot Walk (T2FW) test at 16 weeks, highlighting the focus on efficacy.
- Market Expectations: Kyverna anticipates launching miv-cel in 2027, which, if successful, could present substantial market opportunities, particularly in the rare disease space of stiff person syndrome.
- Additional Research Progress: In addition to stiff person syndrome, miv-cel is also under investigation for myasthenia gravis, further demonstrating its potential across various autoimmune diseases and bolstering investor confidence in the company.
See More
Kyverna Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Kyverna Therapeutics reported a Q1 GAAP EPS of -$0.66, beating expectations by $0.09, indicating a positive trend in financial performance despite ongoing losses.
- Cash Reserves: As of March 31, 2026, Kyverna holds $236.4 million in cash, cash equivalents, and marketable securities, providing ample funding support and ensuring a cash runway into 2028, which enhances operational stability.
- Clinical Progress: Kyverna's mid-stage trial for myasthenia gravis therapy yielded positive data, with deep responses noted despite a small sample size, potentially attracting increased investor interest in future treatment options.
- Funding Strategy: The company has filed for a $300 million mixed securities shelf to support ongoing R&D and market initiatives, reflecting confidence in future growth and strategic planning.
See More
Kyverna Therapeutics Reports Positive Phase 2 Trial Results for Miv-cel in Stiff Person Syndrome
- Trial Success: Kyverna Therapeutics' KYSA-8 trial demonstrated a statistically significant median improvement of 46% in the Timed 25-Foot Walk (T25FW) at 16 weeks, indicating the efficacy of miv-cel in treating Stiff Person Syndrome (SPS) and enhancing patient mobility.
- Significant Patient Improvement: Among treated patients, 81% achieved clinically meaningful improvements of 20% or more, with nearly one-third walking at healthy adult speeds by week 16, reflecting the positive impact of the therapy on functional independence.
- Good Safety Profile: Miv-cel exhibited a well-tolerated safety profile, with four patients experiencing Grade 3/4 neutropenia, a manageable side effect associated with CAR T-cell therapy, and all serious treatment-related adverse events resolved fully without lasting effects.
- Future Outlook: The trial results will be presented at the American Academy of Neurology Annual Meeting in Chicago, which is expected to further enhance KYTX's market performance and increase investor interest in the biopharmaceutical sector.
See More
Kyverna's CAR-T Therapy Shows Significant Mobility Improvements in Clinical Trial
- Trial Results: At the American Academy of Neurology Annual Meeting, Kyverna reported that 81% of patients in their phase-2 trial achieved clinically meaningful mobility improvements at 16 weeks, highlighting the efficacy of their CAR-T cell therapy.
- Positive Patient Response: Among the 26 patients who had not responded well to standard therapies, two-thirds no longer required walking aids after receiving a single dose of miv-cel, and all patients were able to discontinue chronic immunotherapies, demonstrating the therapy's significant impact.
- Manageable Side Effects: Miv-cel was generally well-tolerated, with the most common side effect being a temporary drop in neutrophil counts that was manageable, indicating the therapy's feasibility in terms of safety.
- Broad Market Potential: Kyverna plans to submit a biologics license application to the FDA, and if approved, it would be the first treatment for stiff person syndrome, with a total addressable market exceeding $80 billion, attracting significant investor interest.
See More
US Stock Futures Edge Up Amid Mixed Market Sentiment
- Market Sentiment Fluctuates: Following President Trump's announcement of a ceasefire extension with Iran, US stock index futures edged higher, with Nasdaq 100 futures up 0.68%, S&P 500 futures up 0.53%, and Dow futures up 0.47%, indicating cautious optimism among investors regarding future developments.
- Market Close Performance: Despite the uptick in futures, the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all declined about 0.6% at Monday's close, reflecting ongoing uncertainty surrounding peace negotiations that may impact short-term investment decisions.
- Oil Price Volatility: In Tuesday's trading, WTI crude futures fell 0.07% to $89.61 per barrel, while Brent crude futures dropped 0.02% to $98.46 per barrel, indicating market concerns over global economic prospects that could affect energy-related stocks.
- Stock Movements: Poet Technologies saw its shares rise after the CFO's dismissal, Navitas Semiconductor gained over 2% following the appointment of a new independent director, and Kyverna Therapeutics surged 29% after reporting positive results in a clinical trial, highlighting market interest in specific tech and biotech companies.
See More
Kyverna's miv-cel Shows Significant Improvement in Stiff Person Syndrome
- Clinical Trial Results: Kyverna Therapeutics' miv-cel demonstrated significant clinical improvements in the KYSA-8 registrational trial for Stiff Person Syndrome (SPS), with a 46% improvement in T25FW at 16 weeks and 81% of patients achieving clinically meaningful functional gains, marking a fundamental shift in treatment paradigms.
- New Immunotherapy Option: All 26 patients discontinued chronic immunotherapies after a single dose of miv-cel, showcasing the therapy's potential to enhance patient quality of life and possibly become the first approved treatment for SPS.
- Good Safety Profile: Miv-cel exhibited a favorable safety profile with no high-grade cytokine release syndrome or neurotoxicity observed, and most adverse events were manageable, indicating its suitability for outpatient administration and enhancing its market prospects.
- Future Outlook: Kyverna plans to submit a Biologics License Application (BLA) and is confident in miv-cel's potential for other neurological autoimmune diseases, suggesting that this therapy may play a significant role in broader indications.
See More
Kyverna Initiates Rolling BLA Process with FDA for miv-cel
- BLA Process Initiation: Kyverna Therapeutics (KYTX) has commenced the rolling Biologics License Application (BLA) process for its autoimmune CAR T therapy, miv-cel, marking a significant advancement in treating stiff person syndrome.
- Clinical Data Integration: The company has agreed with the FDA to include results from the KYSA-8 single-arm trial in the application, with the primary endpoint being the Timed 25-foot Walk (T2FW) test at 16 weeks, highlighting the focus on efficacy.
- Market Expectations: Kyverna anticipates launching miv-cel in 2027, which, if successful, could present substantial market opportunities, particularly in the rare disease space of stiff person syndrome.
- Additional Research Progress: In addition to stiff person syndrome, miv-cel is also under investigation for myasthenia gravis, further demonstrating its potential across various autoimmune diseases and bolstering investor confidence in the company.
See More
Kyverna Therapeutics Q1 Earnings Beat Expectations
- Earnings Highlights: Kyverna Therapeutics reported a Q1 GAAP EPS of -$0.66, beating expectations by $0.09, indicating a positive trend in financial performance despite ongoing losses.
- Cash Reserves: As of March 31, 2026, Kyverna holds $236.4 million in cash, cash equivalents, and marketable securities, providing ample funding support and ensuring a cash runway into 2028, which enhances operational stability.
- Clinical Progress: Kyverna's mid-stage trial for myasthenia gravis therapy yielded positive data, with deep responses noted despite a small sample size, potentially attracting increased investor interest in future treatment options.
- Funding Strategy: The company has filed for a $300 million mixed securities shelf to support ongoing R&D and market initiatives, reflecting confidence in future growth and strategic planning.
See More
Kyverna Therapeutics Reports Positive Phase 2 Trial Results for Miv-cel in Stiff Person Syndrome
- Trial Success: Kyverna Therapeutics' KYSA-8 trial demonstrated a statistically significant median improvement of 46% in the Timed 25-Foot Walk (T25FW) at 16 weeks, indicating the efficacy of miv-cel in treating Stiff Person Syndrome (SPS) and enhancing patient mobility.
- Significant Patient Improvement: Among treated patients, 81% achieved clinically meaningful improvements of 20% or more, with nearly one-third walking at healthy adult speeds by week 16, reflecting the positive impact of the therapy on functional independence.
- Good Safety Profile: Miv-cel exhibited a well-tolerated safety profile, with four patients experiencing Grade 3/4 neutropenia, a manageable side effect associated with CAR T-cell therapy, and all serious treatment-related adverse events resolved fully without lasting effects.
- Future Outlook: The trial results will be presented at the American Academy of Neurology Annual Meeting in Chicago, which is expected to further enhance KYTX's market performance and increase investor interest in the biopharmaceutical sector.
See More
Kyverna's CAR-T Therapy Shows Significant Mobility Improvements in Clinical Trial
- Trial Results: At the American Academy of Neurology Annual Meeting, Kyverna reported that 81% of patients in their phase-2 trial achieved clinically meaningful mobility improvements at 16 weeks, highlighting the efficacy of their CAR-T cell therapy.
- Positive Patient Response: Among the 26 patients who had not responded well to standard therapies, two-thirds no longer required walking aids after receiving a single dose of miv-cel, and all patients were able to discontinue chronic immunotherapies, demonstrating the therapy's significant impact.
- Manageable Side Effects: Miv-cel was generally well-tolerated, with the most common side effect being a temporary drop in neutrophil counts that was manageable, indicating the therapy's feasibility in terms of safety.
- Broad Market Potential: Kyverna plans to submit a biologics license application to the FDA, and if approved, it would be the first treatment for stiff person syndrome, with a total addressable market exceeding $80 billion, attracting significant investor interest.
See More
US Stock Futures Edge Up Amid Mixed Market Sentiment
- Market Sentiment Fluctuates: Following President Trump's announcement of a ceasefire extension with Iran, US stock index futures edged higher, with Nasdaq 100 futures up 0.68%, S&P 500 futures up 0.53%, and Dow futures up 0.47%, indicating cautious optimism among investors regarding future developments.
- Market Close Performance: Despite the uptick in futures, the S&P 500, Dow Jones Industrial Average, and Nasdaq Composite all declined about 0.6% at Monday's close, reflecting ongoing uncertainty surrounding peace negotiations that may impact short-term investment decisions.
- Oil Price Volatility: In Tuesday's trading, WTI crude futures fell 0.07% to $89.61 per barrel, while Brent crude futures dropped 0.02% to $98.46 per barrel, indicating market concerns over global economic prospects that could affect energy-related stocks.
- Stock Movements: Poet Technologies saw its shares rise after the CFO's dismissal, Navitas Semiconductor gained over 2% following the appointment of a new independent director, and Kyverna Therapeutics surged 29% after reporting positive results in a clinical trial, highlighting market interest in specific tech and biotech companies.
See More
Kyverna's miv-cel Shows Significant Improvement in Stiff Person Syndrome
- Clinical Trial Results: Kyverna Therapeutics' miv-cel demonstrated significant clinical improvements in the KYSA-8 registrational trial for Stiff Person Syndrome (SPS), with a 46% improvement in T25FW at 16 weeks and 81% of patients achieving clinically meaningful functional gains, marking a fundamental shift in treatment paradigms.
- New Immunotherapy Option: All 26 patients discontinued chronic immunotherapies after a single dose of miv-cel, showcasing the therapy's potential to enhance patient quality of life and possibly become the first approved treatment for SPS.
- Good Safety Profile: Miv-cel exhibited a favorable safety profile with no high-grade cytokine release syndrome or neurotoxicity observed, and most adverse events were manageable, indicating its suitability for outpatient administration and enhancing its market prospects.
- Future Outlook: Kyverna plans to submit a Biologics License Application (BLA) and is confident in miv-cel's potential for other neurological autoimmune diseases, suggesting that this therapy may play a significant role in broader indications.
See More
